Life after cerovive: A personal perspective on ischemic neuroprotection in the post-NXY-059 era

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

The SAINT II Trial, a large randomized multicenter clinical trial of the putative neuroprotectant, NXY-059, failed to demonstrate a treatment benefit in acute ischemic stroke. The further development of this agent was suspended. The implications of this outcome are considered from several perspectives, including: (1) the marginally positive antecedent trial, SAINT I, and the critical commentary stimulated by it, which called attention to its interpretively challenging primary outcome measure-a shift in the full-scale modified Rankin scale score-and to other statistical shortcomings; (2) the cogency of the STAIR recommendations, to which the development of NXY-059 closely adhered; and (3) the inherent physiochemical shortcomings of NXY-059 as a neuroprotective agent-its polar, nonlipophilic nature, poor blood-brain barrier penetrability, nonphysiological oxidation potential, and low potency. Caution is urged, however, regarding the unwarranted adoption of a nihilistic view toward neuroprotection on the part of the stroke community in view of the abundant preclinical evidence demonstrating proof-of-principle of the feasibility of neuroprotection, as well as the multiplicity of biochemical and molecular neuroprotective targets. The author offers the personal example of a translational journey in which a promising neuroprotectant agent targeting multiple injury mechanisms, high-dose albumin therapy, has proceeded successfully from preclinical studies that established efficacy through a pilot clinical trial that demonstrated safety and offered strong suggestions of clinical efficacy, leading to a large multicenter clinical trial currently in progress.

Original languageEnglish
Pages (from-to)1967-1972
Number of pages6
JournalStroke
Volume38
Issue number6
DOIs
StatePublished - Jun 1 2007

Fingerprint

Neuroprotective Agents
Multicenter Studies
Stroke
Clinical Trials
Multiple Trauma
Blood-Brain Barrier
Albumins
Randomized Controlled Trials
Outcome Assessment (Health Care)
Safety
disufenton sodium
Neuroprotection
Therapeutics

Keywords

  • Albumin
  • Clinical trial
  • Ischemia
  • Neuroprotection
  • Stroke

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Neuroscience(all)

Cite this

Life after cerovive : A personal perspective on ischemic neuroprotection in the post-NXY-059 era. / Ginsberg, Myron.

In: Stroke, Vol. 38, No. 6, 01.06.2007, p. 1967-1972.

Research output: Contribution to journalArticle

@article{8c66232117344f32afd35b6c358d2ee1,
title = "Life after cerovive: A personal perspective on ischemic neuroprotection in the post-NXY-059 era",
abstract = "The SAINT II Trial, a large randomized multicenter clinical trial of the putative neuroprotectant, NXY-059, failed to demonstrate a treatment benefit in acute ischemic stroke. The further development of this agent was suspended. The implications of this outcome are considered from several perspectives, including: (1) the marginally positive antecedent trial, SAINT I, and the critical commentary stimulated by it, which called attention to its interpretively challenging primary outcome measure-a shift in the full-scale modified Rankin scale score-and to other statistical shortcomings; (2) the cogency of the STAIR recommendations, to which the development of NXY-059 closely adhered; and (3) the inherent physiochemical shortcomings of NXY-059 as a neuroprotective agent-its polar, nonlipophilic nature, poor blood-brain barrier penetrability, nonphysiological oxidation potential, and low potency. Caution is urged, however, regarding the unwarranted adoption of a nihilistic view toward neuroprotection on the part of the stroke community in view of the abundant preclinical evidence demonstrating proof-of-principle of the feasibility of neuroprotection, as well as the multiplicity of biochemical and molecular neuroprotective targets. The author offers the personal example of a translational journey in which a promising neuroprotectant agent targeting multiple injury mechanisms, high-dose albumin therapy, has proceeded successfully from preclinical studies that established efficacy through a pilot clinical trial that demonstrated safety and offered strong suggestions of clinical efficacy, leading to a large multicenter clinical trial currently in progress.",
keywords = "Albumin, Clinical trial, Ischemia, Neuroprotection, Stroke",
author = "Myron Ginsberg",
year = "2007",
month = "6",
day = "1",
doi = "10.1161/STROKEAHA.106.479170",
language = "English",
volume = "38",
pages = "1967--1972",
journal = "Stroke",
issn = "0039-2499",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Life after cerovive

T2 - A personal perspective on ischemic neuroprotection in the post-NXY-059 era

AU - Ginsberg, Myron

PY - 2007/6/1

Y1 - 2007/6/1

N2 - The SAINT II Trial, a large randomized multicenter clinical trial of the putative neuroprotectant, NXY-059, failed to demonstrate a treatment benefit in acute ischemic stroke. The further development of this agent was suspended. The implications of this outcome are considered from several perspectives, including: (1) the marginally positive antecedent trial, SAINT I, and the critical commentary stimulated by it, which called attention to its interpretively challenging primary outcome measure-a shift in the full-scale modified Rankin scale score-and to other statistical shortcomings; (2) the cogency of the STAIR recommendations, to which the development of NXY-059 closely adhered; and (3) the inherent physiochemical shortcomings of NXY-059 as a neuroprotective agent-its polar, nonlipophilic nature, poor blood-brain barrier penetrability, nonphysiological oxidation potential, and low potency. Caution is urged, however, regarding the unwarranted adoption of a nihilistic view toward neuroprotection on the part of the stroke community in view of the abundant preclinical evidence demonstrating proof-of-principle of the feasibility of neuroprotection, as well as the multiplicity of biochemical and molecular neuroprotective targets. The author offers the personal example of a translational journey in which a promising neuroprotectant agent targeting multiple injury mechanisms, high-dose albumin therapy, has proceeded successfully from preclinical studies that established efficacy through a pilot clinical trial that demonstrated safety and offered strong suggestions of clinical efficacy, leading to a large multicenter clinical trial currently in progress.

AB - The SAINT II Trial, a large randomized multicenter clinical trial of the putative neuroprotectant, NXY-059, failed to demonstrate a treatment benefit in acute ischemic stroke. The further development of this agent was suspended. The implications of this outcome are considered from several perspectives, including: (1) the marginally positive antecedent trial, SAINT I, and the critical commentary stimulated by it, which called attention to its interpretively challenging primary outcome measure-a shift in the full-scale modified Rankin scale score-and to other statistical shortcomings; (2) the cogency of the STAIR recommendations, to which the development of NXY-059 closely adhered; and (3) the inherent physiochemical shortcomings of NXY-059 as a neuroprotective agent-its polar, nonlipophilic nature, poor blood-brain barrier penetrability, nonphysiological oxidation potential, and low potency. Caution is urged, however, regarding the unwarranted adoption of a nihilistic view toward neuroprotection on the part of the stroke community in view of the abundant preclinical evidence demonstrating proof-of-principle of the feasibility of neuroprotection, as well as the multiplicity of biochemical and molecular neuroprotective targets. The author offers the personal example of a translational journey in which a promising neuroprotectant agent targeting multiple injury mechanisms, high-dose albumin therapy, has proceeded successfully from preclinical studies that established efficacy through a pilot clinical trial that demonstrated safety and offered strong suggestions of clinical efficacy, leading to a large multicenter clinical trial currently in progress.

KW - Albumin

KW - Clinical trial

KW - Ischemia

KW - Neuroprotection

KW - Stroke

UR - http://www.scopus.com/inward/record.url?scp=34249780840&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34249780840&partnerID=8YFLogxK

U2 - 10.1161/STROKEAHA.106.479170

DO - 10.1161/STROKEAHA.106.479170

M3 - Article

C2 - 17478741

AN - SCOPUS:34249780840

VL - 38

SP - 1967

EP - 1972

JO - Stroke

JF - Stroke

SN - 0039-2499

IS - 6

ER -